Literature DB >> 31401547

Corpus callosum microstructural and macrostructural abnormalities in schizophrenia according to the stage of disease.

Jérémy Madigand1, Maxime Tréhout2, Nicolas Delcroix3, Sonia Dollfus4, Elise Leroux5.   

Abstract

Corpus callosum (CC) volume and surface (macrostructural) studies remain controversial and have not considered the illness duration (ID) systematically. Regardless of ID, some CC macrostructural studies have shown no difference between SZ patients and healthy controls (HC), whereas others have reported macrostructural abnormalities in SZ. Conversely, CC microstructural studies are more in agreement with alterations in CC integrity regardless of the patients' ID, but the direction and degree of these abnormalities over time remain unknown. Moreover, no study has explored both the micro- and macrostructure of the CC in SZ by considering the stage of disease. Both CC micro- and macrostructural data were investigated in 43 SZ patients and compared between two patient groups (21 patients with a short ID and 22 with a long ID) and HC (23 participants) using diffusion tensor and structural imaging. CC microstructural alterations were detected in both SZ groups compared to the HC group, without differences between the SZ groups. In contrast, CC macrostructural alterations were only found in the long ID group. CC microstructural alterations might be detected in schizophrenia at an early stage, without an increase of magnitude thereafter, while CC macrostructural alterations might become apparent at later stages of the illness.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corpus callosum; Diffusion tensor imaging; Magnetic resonance imaging; Schizophrenia; Volume; White matter

Mesh:

Year:  2019        PMID: 31401547     DOI: 10.1016/j.pscychresns.2019.08.002

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  1 in total

1.  Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated.

Authors:  Bo Tao; Yuan Xiao; Hengyi Cao; Wenjing Zhang; Chengmin Yang; Rebekka Lencer; Qiyong Gong; Su Lui
Journal:  BMC Psychiatry       Date:  2021-10-30       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.